The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants
Status: | Recruiting |
---|---|
Conditions: | Pulmonary |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 1/12/2019 |
Start Date: | October 30, 2017 |
End Date: | June 30, 2020 |
Contact: | Zubaida Dabre, RN BA |
Email: | zubaida.dabre@yale.edu |
Phone: | 203-737-5403 |
The Safety of Thoracentesis, Tunneled Pleural Catheter (Pleurx), and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants (NOAC).
To assess risks of bleeding in those individuals receiving Novel Oral Anti-Coagulant (NOAC)
medications, admitted to the hospital and require thoracentesis, chest tube or tunneled
pleural catheter placement.
medications, admitted to the hospital and require thoracentesis, chest tube or tunneled
pleural catheter placement.
The research component of this study simply observes and documents the outcomes of these
procedures. Patients will undergo an analysis of their pre-procedural hematocrit and this
will be compared to their post-procedural (next day) hematocrit.
procedures. Patients will undergo an analysis of their pre-procedural hematocrit and this
will be compared to their post-procedural (next day) hematocrit.
Inclusion Criteria:
1. Age > 18 y/o
2. Unilateral or bilateral pleural effusion
3. Ability to provide consent or consent given for the procedure and research study
Exclusion Criteria:
Adults who refuse to provide consent.
We found this trial at
1
site
20 York St, N20 York St,
New Haven, Connecticut 06520
New Haven, Connecticut 06520
(203) 688-4242
Phone: 203-737-5688
Yale-New Haven Hospital Relying on the skill and expertise of more than 4,500 university and...
Click here to add this to my saved trials